{"id":1186,"date":"2012-06-27T15:19:42","date_gmt":"2012-06-27T15:19:42","guid":{"rendered":"https:\/\/touchneurology.com\/2012\/06\/27\/treatment-of-aggressive-pituitary-adenomas-and-carcinomas-an-overview\/"},"modified":"2012-06-27T15:19:42","modified_gmt":"2012-06-27T15:19:42","slug":"treatment-of-aggressive-pituitary-adenomas-and-carcinomas-an-overview","status":"publish","type":"post","link":"https:\/\/touchneurology.com\/neurological-oncology\/journal-articles\/treatment-of-aggressive-pituitary-adenomas-and-carcinomas-an-overview\/","title":{"rendered":"Treatment of Aggressive Pituitary Adenomas and Carcinomas \u2013 An Overview"},"content":{"rendered":"

Most pituitary tumours are non-invasive, benign adenomas that remain confined to the sella turcica. Although there is, at present, no accepted definition of aggressive pituitary adenomas, one would suggest that these have a tendency to recur after initial surgery. They have a rapid growth rate and invade surrounding structures such as the sphenoid and cavernous sinus as well as the skull base bone. They are clinically difficult to manage and present major problems due to incomplete resection.1<\/sup> <\/p>\n

Pituitary carcinomas are rare \u2013 0.2 % of all pituitary tumours. They present major diagnostic and therapeutic challenges. They may initially appear as benign pituitary adenomas subsequently transforming into an aggressive neoplasm, or they may be aggressive tumours from the beginning.2\u20134<\/sup> A pituitary carcinoma is diagnosed when craniospinal and\/or systemic metastases are documented.5 Predicting pituitary tumour behaviour remains a real challenge. Studies suggest that increased mitotic activity, high Ki-67, nuclear labelling index and P53 expression might be associated with tumour progression.3,5<\/sup> <\/p>\n

Multiple treatment approaches \u2013 including surgery, external beam radiotherapy, gamma knife, drugs and various chemotherapeutic agents \u2013 have been used. Until recently, the treatment of pituitary carcinomas was mainly palliative and did not seem to increase overall survival. Progression of disease after a diagnosis of pituitary carcinoma was variable; approximately 75 % of patients with systemic metastasis died of the disease within one year.4 Recent publications report efficacy of temozolomide, an alkylating agent used to treat gliomas, in the management of aggressive pituitary adenomas and carcinomas.6\u201336<\/sup> As in gliomas, the outcome of treatment might depend on the expression of O6-methylguanine-DNA methyltransferase (MGMT), a DNA repair enzyme that counteracts the action of temozolomide.6,13,37<\/sup> <\/p>\n

Temozolomide <\/b>
Temozolomide is an alkylating chemotherapeutic agent related to a series of imidazotetrazines. Orally administered, it readily crosses the blood\u2013brain barrier. It exerts its cytotoxic effect through methylation of DNA at the O6 position of guanine,38<\/sup> which then mispairs with thymine during the next cycle of DNA replication. Temozolomide is accepted as an effective drug in the treatment of glioblastoma multiforme and other tumours of the central nervous system.39<\/sup> Recent reports point out its efficacy in malignant neuroendocrine neoplasms,40<\/sup> melanomas41,42<\/sup> and colorectal carcinomas.43<\/sup> <\/p>\n

To view the full article in PDF or eBook formats, please click on the icons above.<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

Most pituitary tumours are non-invasive, benign adenomas that remain confined to the sella turcica. Although there is, at present, no accepted definition of aggressive pituitary adenomas, one would suggest that these have a tendency to recur after initial surgery. They have a rapid growth rate and invade surrounding structures such as the sphenoid and cavernous […]<\/p>\n","protected":false},"author":1,"featured_media":1187,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","rank_math_lock_modified_date":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1186","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","vocabulary_1-neurological-oncology"],"acf":{"wpcf-article_introduction":"","wpcf-article_abstract":"Most pituitary tumours are non-invasive, benign adenomas that remain confined to the sella turcica. Some of them recur, have a rapid growth rate, and invade surrounding tissues. These adenomas, considered aggressive pituitary tumours, are difficult to manage and present problems due to incomplete resection. A pituitary carcinoma is diagnosed when craniospinal and\/or systemic metastases are documented. Treatment options for pituitary adenomas are surgery, radiation and drugs. Recent publications report the efficacy of temozolomide in the treatment of aggressive pituitary adenomas and carcinomas. Indications for, results with, and side effects of temozolomide therapy in aggressive pituitary tumours and pituitary carcinomas are reviewed here. Alternative treatment options for resistant or recurrent pituitary tumours are also discussed.\r\n","wpcf-article_keywords":"Pituitary adenoma, pituitary carcinoma, O6-methylguanine-DNA methyltransferase (MGMT), temozolomide, everolimus, bevacizumab","wpcf-article_citation_override":"European Neurological Review, <\/i>2012;7(3):178-180 DOI: http:\/\/doi.org\/10.17925\/ENR.2012.07.03.178<\/a>","wpcf-compliance-with-ethics":"","wpcf-article_disclosure":"","wpcf-review_process":"","wpcf-authorship":"","wpcf-article_correspondence":"","wpcf-article_support":"","wpcf-open_access":"","wpcf-article_pdf":"http:\/\/touchneurology.com\/wp-content\/uploads\/sites\/3\/2015\/06\/private_articles_10418_pdf_syro.pdf","wpcf-article_pdf-gated":true,"wpcf-article_doi":"","wpcf-old_nid":"","wpcf-article_image":"http:\/\/touchneurology.com\/wp-content\/uploads\/sites\/3\/2018\/08\/thumbnail-14_4.png","wpcf-editor_choice":false,"wpcf-old_author_ids":"","wpcf-article_references":"

    \r\n\r\n
  1. Buchfelder M, Management of aggressive pituitary\r\nadenomas: current treatment strategies, Pituitary,\r\n2009;12(3):256\u201360.\r\n
  2. Kaltsas GA, Nomikos P, Kontogeorgos G, et al., Clinical\r\nreview: Diagnosis and management of pituitary carcinomas,\r\nJ Clin Endocrinol Metab, 2005;90(5):3089\u201399.\r\n
  3. Colao A, Ochoa AS, Auriemma RS, et al., Pituitary\r\ncarcinomas, Front Horm Res, 2010;38:94\u2013108.\r\n
  4. Pernicone PJ, Scheithauer BW, Sebo TJ, et al., Pituitary\r\ncarcinoma: a clinicopathologic study of 15 cases, Cancer,\r\n1997;79(4):804\u201312.\r\n
  5. Heaney AP, Clinical review: Pituitary carcinoma: difficult\r\ndiagnosis and treatment, J Clin Endocrinol Metab,\r\n2011;96(12):3649\u201360. Erratum in: J Clin Endocrinol Metab,\r\n2012;97(3):1064.\r\n
  6. Raverot G, Castinetti F, Jouanneau E, et al., Pituitary\r\ncarcinomas and aggressive pituitary tumours: merits and\r\npitfalls of temozolomide treatment, Clin Endocrinol (Oxf),\r\n2012;76(6):769\u201375.\r\n
  7. Ortiz LD, Syro LV, Scheithauer BW, et al., Temozolomide in\r\naggressive pituitary adenomas and carcinomas,\r\nClinics (Sao Paulo), 2012;67(Suppl. 1):119\u201323.\r\n
  8. Lim S, Shahinian H, Maya MM, et al., Temozolomide: a novel\r\ntreatment for pituitary carcinoma, Lancet Oncol, 2006;7(6):518\u201320.\r\n
  9. Fadul CE, Kominsky AL, Meyer LP, et al., Long-term\r\nresponse of pituitary carcinoma to temozolomide. Report of\r\ntwo cases, J Neurosurg, 2006;105(4):621\u20136.\r\n
  10. Syro LV, Uribe H, Penagos LC, et al., Antitumour effects of\r\ntemozolomide in a man with a large, invasive prolactinproducing\r\npituitary neoplasm, Clin Endocrinol (Oxf),\r\n2006;65(4):552\u20133.\r\n
  11. Kovacs K, Horvath E, Syro LV, et al., Temozolomide therapy in\r\na man with an aggressive prolactin-secreting pituitary\r\nneoplasm: Morphological findings, Hum Pathol, 2007;38(1):185\u20139.\r\n
  12. Neff LM, Weil M, Cole A, et al., Temozolomide in the\r\ntreatment of an invasive prolactinoma resistant to\r\ndopamine agonists, Pituitary, 2007;10(1):81\u20136.\r\n
  13. Kovacs K, Scheithauer BW, Lombardero M, et al., MGMT\r\nimmunoexpression predicts responsiveness of pituitary\r\ntumors to temozolomide therapy, Acta Neuropathol,\r\n2008;115(2):261\u20132.\r\n
  14. Debono M, Bridgewater C, Ross R, Newell Price J, Treating\r\nan aggressive prolactinoma in a patient with MEN 1:\r\nbeneficial response to temozolomide, Presented at:\r\nSociety for Endocrinology BES 2008, Harrogate, UK,\r\nApril 7\u201310, 2008; Endocrine Abstracts, 2008;15:188.\r\n
  15. Moyes VJ, Alusi G, Sabin HI, et al., Treatment of Nelson\u2019s\r\nsyndrome with temozolomide, Eur J Endocrinol, 2009;160(1):115\u20139.\r\n
  16. McCormack AI, McDonald KL, Gill AJ, et al., Low O6-\r\nmethylguanine-DNA methyltransferase (MGMT) expression\r\nand response to temozolomide in aggressive pituitary\r\ntumours, Clin Endocrinol (Oxf), 2009;71(2):226\u201333.\r\n
  17. Mohammed S, Kovacs K, Mason W, et al., Use of\r\ntemozolomide in aggressive pituitary tumors: case report,\r\nNeurosurgery, 2009;64(4):E773\u20134; discussion E774.\r\n
  18. Takeshita A, Inoshita N, Taguchi M, et al., High incidence of\r\nlow O(6)-methylguanine DNA methyltransferase expression\r\nin invasive macroadenomas of Cushing\u2019s disease,\r\nEur J Endocrinol, 2009;161(4):553\u20139.\r\n
  19. Hagen C, Schroeder HD, Hansen S, et al., Temozolomide\r\ntreatment of a pituitary carcinoma and two pituitary\r\nmacroadenomas resistant to conventional therapy,\r\nEur J Endocrinol, 2009;161(4):631\u20137.\r\n
  20. Byrne S, Karapetis C, Vrodos N, A novel use of\r\ntemozolomide in a patient with malignant prolactinoma,\r\nJ Clin Neurosci, 2009;16(12):1694\u20136.\r\n
  21. Thearle MS, Freda PU, Bruce JN, et al., Temozolomide\r\n(Temodar\u00ae) and capecitabine (Xeloda\u00ae) treatment of an\r\naggressive corticotroph pituitary tumor, Pituitary,\r\n2011;14(4):418\u201324.\r\n
  22. Syro LV, Scheithauer BW, Ortiz LD, et al., Effect of\r\ntemozolomide in a patient with recurring oncocytic\r\ngonadotrophic pituitary adenoma, Hormones (Athens),\r\n2009;8(4):303\u20136.\r\n
  23. Morin E, Berthelet F, Weisnagel J, et al., Failure of\r\ntemozolomide and conventional doses of pegvisomant to\r\nattain biochemical control in a severe case of acromegaly,\r\nPituitary, 2012;15(1):97\u2013100.\r\n
  24. Bode H, Seiz M, Lammert A, et al., SOM230 (pasireotide) and\r\ntemozolomide achieve sustained control of tumour\r\nprogression and ACTH secretion in pituitary carcinoma\r\nwith widespread metastases, Exp Clin Endocrinol Diabetes,\r\n2010;118(10):760\u20133.\r\n
  25. Raverot G, Sturm N, de Fraipont F, et al., Temozolomide\r\ntreatment in aggressive pituitary tumors and pituitary\r\ncarcinomas: a French multicenter experience,\r\nJ Clin Endocrinol Metab, 2010;95(10):4592\u20139.\r\n
  26. Bush ZM, Longtine JA, Cunningham T, et al., Temozolomide\r\ntreatment for aggressive pituitary tumors: correlation of\r\nclinical outcome with O(6)-methylguanine methyltransferase\r\n(MGMT) promoter methylation and expression,\r\nJ Clin Endocrinol Metab, 2010;95(11):E280\u201390.\r\n
  27. Syro LV, Ortiz LD, Scheithauer BW, et al., Treatment\r\nof pituitary neoplasms with temozolomide: a review,\r\nCancer, 2011;117(3):454\u201362.\r\n
  28. Losa M, Mazza E, Terreni MR, et al., Salvage therapy with\r\ntemozolomide in patients with aggressive or metastatic\r\npituitary adenomas: experience in six cases,\r\nEur J Endocrinol, 2010;163(6):843\u201351.\r\n
  29. Dillard TH, Gultekin SH, Delashaw JB Jr, et al., Temozolomide\r\nfor corticotroph pituitary adenomas refractory to standard\r\ntherapy, Pituitary, 2011;14(1):80\u201391.\r\n
  30. Curt\u00f2 L, Torre ML, Ferra\u00f9 F, et al., Temozolomide-induced\r\nshrinkage of a pituitary carcinoma causing Cushing\u2019s\r\ndisease \u2013 report of a case and literature review,\r\nScientificWorldJournal, 2010;10:2132\u20138.\r\n
  31. Murakami M, Mizutani A, Asano S, et al., A mechanism of\r\nacquiring temozolomide resistance during transformation of\r\natypical prolactinoma into prolactin-producing pituitary\r\ncarcinoma: case report, Neurosurgery, 2011;68(6):E1761\u20137.\r\n
  32. Moshkin O, Syro LV, Scheithauer BW, et al., Aggressive\r\nsilent corticotroph adenoma progressing to pituitary\r\ncarcinoma: the role of temozolomide therapy,\r\nHormones (Athens), 2011;10(2):162\u20137.\r\n
  33. Arnold PM, Ratnasingam D, O\u2019Neil MF, Johnson PL, Pituitary\r\ncarcinoma recurrent to the lumbar intradural extramedullary\r\nspace: case report, J Spinal Cord Med, 2012;35(2):118\u201321.\r\n
  34. Jouanneau E, Wierinckx A, Ducray F, et al., New targeted\r\ntherapies in pituitary carcinoma resistant to temozolomide,\r\nPituitary, 2012;15(1):37\u201343.\r\n
  35. Philippon M, Morange I, Barrie M, et al., Long-term control\r\nof a MEN1 prolactin secreting pituitary carcinoma after\r\ntemozolomide treatment, Ann Endocrinol (Paris),\r\n2012; [Epub ahead of print].\r\n
  36. Whitelaw BC, Dworakowska D, Thomas NW, et al.,\r\nTemozolomide in the management of dopamine agonistresistant\r\nprolactinomas, Clin Endocrinol (Oxf), 2012;76(6):877\u201386.\r\n
  37. McCormack AI, Wass JA, Grossman AB, Aggressive pituitary\r\ntumours: the role of temozolomide and the assessment of\r\nMGMT status, Eur J Clin Invest, 2011;41(10):1133\u201348.\r\n
  38. Stevens MF, Hickman JA, Langdon SP, et al., Antitumor\r\nactivity and pharmacokinetics in mice of 8-carbamoyl-3-\r\nmethyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG\r\n81045; M & B 39831), a novel drug with potential as an\r\nalternative to dacarbazine, Cancer Res, 1987;47(22):5846\u201352.\r\n
  39. Stupp R, Mason WP, van den Bent MJ, et al., Radiotherapy\r\nplus concomitant and adjuvant temozolomide for\r\nglioblastoma, N Engl J Med, 2005;352(10):987\u201396.\r\n
  40. Kulke MH, Stuart K, Enzinger PC, et al., Phase II study of\r\ntemozolomide and thalidomide in patients with metastatic\r\nneuroendocrine tumors, J Clin Oncol, 2006;24(3):401\u20136.\r\n
  41. Agarwala SS, Kirkwood JM, Temozolomide, a novel\r\nalkylating agent with activity in the central nervous system,\r\nmay improve the treatment of advanced metastatic\r\nmelanoma, Oncologist, 2000;5(2):144\u201351.\r\n
  42. Quirt I, Verma S, Petrella T, et al., Temozolomide for the\r\ntreatment of metastatic melanoma: a systematic\r\nreview, Oncologist, 2007;12(9):1114\u201323.\r\n
  43. Shacham-Shmueli E, Beny A, Geva R, et al., Response to\r\ntemozolomide in patients with metastatic colorectal cancer\r\nwith loss of MGMT expression: a new approach in the era of\r\npersonalized medicine? J Clin Oncol, 2011;29(10):e262\u20135.\r\n
  44. Clarke JL, Iwamoto FM, Sul J, et al., Randomized phase II\r\ntrial of chemoradiotherapy followed by either dose-dense or\r\nmetronomic temozolomide for newly diagnosed\r\nglioblastoma, J Clin Oncol, 2009;27(23):3861\u20137.\r\n
  45. Mrugala MM, Chamberlain MC, Mechanisms of disease:\r\ntemozolomide and glioblastoma \u2013 look to the future,\r\nNat Clin Pract Oncol, 2008;5(8):476\u201386.\r\n
  46. Liu L, Gerson SL, Targeted modulation of MGMT: clinical\r\nimplications, Clin Cancer Res, 2006;12(2):328\u201331.\r\n
  47. Rodriguez FJ, Thibodeau SN, Jenkins RB, et al., MGMT\r\nimmunohistochemical expression and promoter methylation\r\nin human glioblastoma, Appl Immunohistochem Mol Morphol,\r\n2008;16(1):59\u201365.\r\n
  48. Gerson SL, Clinical relevance of MGMT in the treatment of\r\ncancer, J Clin Oncol, 2002;20(9):2388\u201399.\r\n
  49. Esteller M, Hamilton SR, Burger PC, et al., Inactivation of the\r\nDNA repair gene O6-methylguanine-DNA methyltransferase\r\nby promoter hypermethylation is a common event in\r\nprimary human neoplasia, Cancer Res, 1999;59(4):793\u20137.\r\n
  50. Sharma S, Salehi F, Scheithauer BW, et al., Role of MGMT in\r\ntumor development, progression, diagnosis, treatment and\r\nprognosis, Anticancer Res, 2009;29(10):3759\u201368.\r\n
  51. Esteller M, Garcia-Foncillas J, Andion E, et al., Inactivation of\r\nthe DNA-repair gene MGMT and the clinical response of\r\ngliomas to alkylating agents, N Engl J Med, 2000;343(19):1350\u20134.\r\n
  52. Kaltsas GA, Mukherjee JJ, Plowman PN, et al., The role of\r\ncytotoxic chemotherapy in the management of aggressive\r\nand malignant pituitary tumors, J Clin Endocrinol Metab,\r\n1998;83(12):4233\u20138.\r\n
  53. Melmed S, Casanueva FF, Hoffman AR, et al., Diagnosis and\r\ntreatment of hyperprolactinemia: an Endocrine Society\r\nclinical practice guideline, J Clin Endocrinol Metab,\r\n2011;96(2):273\u201388.\r\n
  54. Jouanneau E, Wierinckx A, Ducray F, et al., New targeted\r\ntherapies in pituitary carcinoma resistant to temozolomide,\r\nPituitary, 2012;15(1):37\u201343.\r\n
  55. Ortiz LD, Syro LV, Scheithauer BW, et al., Anti-VEGF therapy in\r\npituitary carcinoma, Pituitary, 2011; [Epub ahead of print].\r\n
  56. Gerlinger M, Rowan AJ, Horswell S, et al., Intratumor\r\nheterogeneity and branched evolution revealed by\r\nmultiregion sequencing, N Engl J Med, 2012;366(10):883\u201392.\r\n
  57. Longo DL, Tumor heterogeneity and personalized medicine,\r\nN Engl J Med, 2012;366(10):956\u20137.\r\n
  58. Yap TA, Gerlinger M, Futreal PA, et al., Intratumor\r\nheterogeneity: seeing the wood for the trees,\r\nSci Transl Med, 2012;4(127):127ps10.\r\n\r\n\r\n<\/ol>","wpcf-article_received_date":null,"wpcf-article_accepted_date":null,"wpcf-article_published_online":null,"wpcf-podcast":"","wpcf-ogg":"","wpcf-article_end_page":"180","wpcf-article_start_page":"178","wpcf-acknowledgements":"","wpcf-errata_pdf":"","wpcf-article_flipper_image":"http:\/\/touchneurology.com\/wp-content\/uploads\/sites\/3\/2016\/12\/Flipper-Files2.png","wpcf-corrected_online":null,"wpcf-supplementary_information":"","wpcf-article_highlight_pdf":"","data_availability":"","digital_features":""},"_links":{"self":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/posts\/1186","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/comments?post=1186"}],"version-history":[{"count":0,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/posts\/1186\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media\/1187"}],"wp:attachment":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media?parent=1186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/categories?post=1186"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/tags?post=1186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}